Brandys Nad Labem

• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit … Ended recruitment
  2023-509066-38-00 4 2021-04-16 Atrial Fibrillation
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure … Ended
  2023-507640-36-00 5 2024-04-29 Resistant hypertension (rHTN) defined as blood pressure that remains h
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended
  2023-506197-12-00 4 2024-02-07 Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile
• A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended
  2022-502854-16-00 4 2023-11-26 Asthma
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended
  2022-502833-25-00 5 2023-08-02 Obesity
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22 Chronic obstructive pulmonary disease (COPD)
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S … Ended
  2023-505786-88-00 5 2021-04-25 Severe and inadequately controlled asthma
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus

Showing 25–48 of 50 trials